GRADALIS DEPLOYS L7’S ENTERPRISE SCIENCE PLATFORM FOR NEXT-GENERATION LIFE SCIENCE COMPANIES IN RECORD TIME TO SUPPORT MISSION-CRITICAL IMMUNOTHERAPY MANUFACTURING AND CLINICAL TRIAL PROCESSES

DALLAS, October 3, 2018 – Gradalis, Inc., a Dallas-based, clinical-stage, vertically-integrated immunotherapy company, announced today it has successfully implemented and launched L7’s Enterprise Science Platform (“ESP”). L7 Informatics, Inc., is the leading software and analytics company for life science research and manufacturing companies.

Gradalis recently upgraded its Carrollton, TX manufacturing facility to support the launch of a Phase 3 registration trial of Vigil in Ewing’s sarcoma. Gradalis’ vertically integrated research, clinical and manufacturing business model creates complex master batch record (“MBR”) requirements that few technology providers can support.

Get in touch with us
Let’s work together to solve your workflow challenges.
Contact Us